DarioHealth Corp. (DRIO): Price and Financial Metrics

DarioHealth Corp. (DRIO): $10.29

-0.07 (-0.68%)

POWR Rating

Component Grades














  • DRIO scores best on the Value dimension, with a Value rank ahead of 31.21% of US stocks.
  • DRIO's strongest trending metric is Momentum; it's been moving down over the last 155 days.
  • DRIO ranks lowest in Quality; there it ranks in the 2nd percentile.

DRIO Stock Summary

  • For DRIO, its debt to operating expenses ratio is greater than that reported by only 5.57% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.12 for DarioHealth Corp; that's greater than it is for just 9.17% of US stocks.
  • Revenue growth over the past 12 months for DarioHealth Corp comes in at 127.1%, a number that bests 94.38% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to DarioHealth Corp are VERI, BSGM, NVTA, BEEM, and COUP.
  • DRIO's SEC filings can be seen here. And to visit DarioHealth Corp's official web site, go to mydario.com.

DRIO Valuation Summary

  • DRIO's EV/EBIT ratio is -3.3; this is 111.26% lower than that of the median Healthcare stock.
  • Over the past 101 months, DRIO's price/earnings ratio has gone up 1.
  • DRIO's price/sales ratio has moved NA NA over the prior 101 months.

Below are key valuation metrics over time for DRIO.

Stock Date P/S P/B P/E EV/EBIT
DRIO 2021-08-31 17.2 1.9 -4.4 -3.3
DRIO 2021-08-30 15.8 1.7 -4.0 -2.9
DRIO 2021-08-27 16.4 1.8 -4.2 -3.1
DRIO 2021-08-26 15.7 1.7 -4.0 -2.9
DRIO 2021-08-25 15.5 1.7 -4.0 -2.9
DRIO 2021-08-24 15.7 1.7 -4.0 -2.9

DRIO Growth Metrics

    Its 5 year revenue growth rate is now at 427.49%.
  • The 2 year price growth rate now stands at -79.65%.
  • Its 3 year revenue growth rate is now at 495.17%.
Over the past 33 months, DRIO's revenue has gone up $9,171,000.

The table below shows DRIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 16.565 -42.033 -66.359
2021-06-30 12.978 -33.39 -50.907
2021-03-31 9.504 -23.723 -37.446
2020-12-31 7.576 -17.736 -33.103
2020-09-30 7.294 -13.828 -30.767
2020-06-30 7.12 -13.418 -26.092

DRIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DRIO has a Quality Grade of F, ranking ahead of 2.68% of graded US stocks.
  • DRIO's asset turnover comes in at 0.156 -- ranking 147th of 186 Medical Equipment stocks.
  • SPNE, ATRI, and ICAD are the stocks whose asset turnover ratios are most correlated with DRIO.

The table below shows DRIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.156 0.284 28.266
2021-03-31 0.174 0.296 38.633
2020-12-31 0.266 0.332 847.338
2020-09-30 0.283 0.384 132.027
2020-06-30 0.404 0.439 -93.685
2020-03-31 0.426 0.403 -274.333

DRIO Price Target

For more insight on analysts targets of DRIO, see our DRIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.53 Average Broker Recommendation 1.5 (Moderate Buy)

DRIO Stock Price Chart Interactive Chart >

Price chart for DRIO

DRIO Price/Volume Stats

Current price $10.29 52-week high $31.85
Prev. close $10.36 52-week low $9.92
Day low $9.92 Volume 77,800
Day high $10.67 Avg. volume 113,760
50-day MA $14.46 Dividend yield N/A
200-day MA $15.95 Market Cap 170.57M

DarioHealth Corp. (DRIO) Company Bio

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.

DRIO Latest News Stream

Event/Time News Detail
Loading, please wait...

DRIO Latest Social Stream

Loading social stream, please wait...

View Full DRIO Social Stream

Latest DRIO News From Around the Web

Below are the latest news stories about DarioHealth Corp that investors may wish to consider to help them evaluate DRIO as an investment opportunity.

DarioHealth wins two digital therapeutics contracts within employer market

DarioHealth (NASDAQ:DRIO) has won two new contracts to provide its digital therapeutics beginning in Q1. The new clients include a large Northeast regional employer in the finance industry set to deploy Dario's full suite of solutions, and a Northeast regional employer in the food industry contracted to deploy Dario's digital...

Seeking Alpha | January 6, 2022

DarioHealth Announces Two New Contracts within the Employer Market

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced two new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022.

Yahoo | January 6, 2022

DarioHealth (DRIO) Gets a Buy Rating from LifeSci Capital

E ratio of -2.80.

Brian Anderson on TipRanks | December 22, 2021

DarioHealth Selected as Exclusive Digital Therapeutics Provider to a Leading Benefits Brokerage

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced a new strategic partnership with a leading employer benefits brokerage (the "Partner") to sell its digital therapeutic solutions for diabetes, hypertension and musculoskeletal health as part of a new premier employee health benefits product for small businesses. The product will be made available to the Partner's more than 2,300 clients beginning in early 2022.

Yahoo | December 21, 2021

-$1.13 Earnings Per Share Expected for DarioHealth Corp. (NASDAQ:DRIO) This Quarter

Equities research analysts expect that DarioHealth Corp. (NASDAQ:DRIO) will post earnings of ($1.13) per share for the current quarter, according to Zacks. Two analysts have issued estimates for DarioHealths earnings. The highest EPS estimate is ($1.01) and the lowest is ($1.31). DarioHealth posted earnings of ($1.06) per share during the same quarter last year, which []

Transcript Daily | December 18, 2021

Read More 'DRIO' Stories Here

DRIO Price Returns

1-mo -23.72%
3-mo -33.05%
6-mo -36.28%
1-year -42.48%
3-year -34.87%
5-year -83.97%
YTD -20.66%
2021 -9.24%
2020 117.84%
2019 -57.95%
2018 -51.25%
2017 -50.77%

Continue Researching DRIO

Want to see what other sources are saying about DarioHealth Corp's financials and stock price? Try the links below:

DarioHealth Corp (DRIO) Stock Price | Nasdaq
DarioHealth Corp (DRIO) Stock Quote, History and News - Yahoo Finance
DarioHealth Corp (DRIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.894 seconds.